These QTc observations warrant further evaluation.
They suggest there is a dose/response QTc relationship, and that opens up the issue of what these numbers look like at higher doses and the degree of variability in the drug's PK and the issue of possible drug-drug interactions (which were the root cause of all the drugs that were withdrawn for QTc issues).
Personally I think the whole QTc issue with these marginal prolongations is hugely overblown in terms of the actual risk compared with the amount of attention focused on it, but that boat sailed long ago and we have to live with the regime we have. I suspect plenty of currently very widely-used drugs would never have been approved under the current standards - including drugs like Zithromax that are given out like candy today.
Market Data 
Markets 
AI
